Origin Materials, Inc.

Origin did not provide quarterly revenue or EPS in the prepared remarks. It reported cash, cash equivalents and marketable securities of $53.5 million at December 31, 2025, net accounts receivable of $13 million, land held for use in Geismar, Louisiana of $9.1 million, and $15 million of convertible debt outstanding. The company recorded a $165.9 million impairment expense in Q4, with adjusted fair value of OM1/OM2-related assets stated at $18 million. On guidance, management said it no longer expects adjusted EBITDA run-rate breakeven prior to 2028, versus a prior expectation of 2027, and said existing cash and cash equivalents should support planned operations into the third quarter of 2026 absent near-term financing and operating expense reductions.

John Bissell framed the quarter as operationally meaningful but commercially slower than planned. He said the latest PET cap iteration has been delivered to multiple world-class beverage brands and that customer feedback has been incorporated into improved seal performance and impact resistance, but also acknowledged that the company underestimated how long qualification would take. His tone was confident on the technology and market opportunity, while candid about delays, saying Origin remains the clear technology leader for PET caps and expects adoption to come through a series of smaller launches rather than one large rollout.

Matt Plavan focused on liquidity, financing, and the impact of the strategic shift away from furanics. He said the company had $53.5 million in cash, cash equivalents and marketable securities at year-end, $13 million in net receivables tied to the legacy supply chain activation program, $9.1 million of land in Geismar, and $15 million of convertible debt. He also highlighted the $165.9 million impairment driven by the decision to stop investing in furanics, and said the company is actively seeking equipment financing while also pursuing capital infusions and asset monetization. Importantly, he said the adjusted EBITDA breakeven target moved from 2027 to prior to 2028 due to slower customer validation and a more gradual commercialization path.

Analysts pressed management on why sales and commercialization have taken longer, why manufacturing lines 2 and 3 were not started, and what the strategic review could produce. Bissell said the core issue is that PET cap qualification is taking longer than expected because it is a new cap design and customers are running more extensive and sometimes serial testing than the company anticipated. On manufacturing, management said production capacity is not the near-term priority versus product iteration, though the lines could be brought on quickly once uptake increases. On the strategic review, Bissell said there is inbound interest and that multiple arrangements remain under discussion, but it is too early to know which path will win.